|Venous thrombosis and pulmonary embolism constitute
major health problems that result in significant morbidity and mortality
in the United States. It is estimated that venous thrombosis and pulmonary
embolism are associated with 300,000 to 600,000 hospitalizations a year
and that as many as 50,000 individuals die each year as a result of
Both venous thrombosis and pulmonary embolism are often silent and difficult to detect by clinical examination. The use of a number of diagnostic tests such as fibrinogen uptake, Doppler ultrasound, impedance plethysmography, venography, ventilation-perfusion scans, and pulmonary angiography has resulted in the identification of several groups of patients at high risk of developing venous thromboembolic disease. Patients undergoing various types of surgery--general, orthopedic, gynecological-obstetrical, urological, and neurosurgical--are at high risk for developing deep venous thrombosis (DVT) and pulmonary embolism (PE). Of these groups, orthopedic patients appear to be especially prone to thrombosis, particularly patients with hip fracture. Patients with various types of medical diseases, usually chronic, are also at high risk for venous thrombotic events.
Because some groups of patients at high risk for the development of venous thromboembolism can be identified, it is reasonable and desirable to consider ways of prevention; prevention is far superior to treatment.
To help resolve questions that relate to various prophylactic measures in high-risk groups of patients, the National Heart, Lung, and Blood Institute and the NIH Office of Medical Applications of Research convened a Consensus Development Conference on Prevention of Venous Thrombosis and Pulmonary Embolism on March 24-26, 1986. After hearing a series of expert presentations and discussion from the audience and reviewing the medical literature, a consensus development panel representing the professional fields of vascular, orthopedic, urologic, and trauma surgery, hematology, pulmonary medicine, obstetrics and gynecology, family practice, epidemiology, biostatistics, and the general public considered the evidence and agreed on answers to the following questions:
Inherent in the first three questions is an epidemiologic and statistical assessment of whether the existing data are sufficient to warrant recommendations on the prophylaxis of venous thromboembolism.
The most rigorous and definitive test of any method of prophylaxis is the randomized clinical trial. However, the incidence of clinically significant PE is low and would thus require trials on the order of 5,000 patients to examine the effect of prophylaxis on all PE or 100,000 patients to examine the effect on all-cause mortality. In contrast, the incidence of DVT is substantially higher, ranging from 20 to 70 percent. Thus, prophylactic treatment of DVT can be evaluated with trials of smaller sample size, but it is first necessary to demonstrate the clinical relevance of the presence of DVT to the development of pulmonary embolism.
The use of DVT screening tests as a marker for pulmonary embolism is justified both by the known pathophysiology of pulmonary embolism and the association of a reduction in DVT with a reduction in PE. In particular, the combined data on over 12,000 individuals in randomized clinical trials of low-dose heparin showed a 68 percent reduction in DVT as measured by the 125I-fibrinogen uptake test and/or venography; this was associated with a 49 percent reduction in PE. Moreover, there was a decrease in overall mortality that was due to the decrease in fatal pulmonary embolism. The evidence for a benefit of prophylaxis in preventing pulmonary embolism is compelling using DVT as a marker. The findings within most specific patient subgroups rely on this assumption: that DVT is an appropriate marker for PE.
When using DVT as a marker for PE, many clinical trials have had an inadequate number of patients to detect important therapeutic differences. Trends that may appear to be a chance finding in any one trial assume importance when consistently seen in multiple trials. In evaluating the evidence, the panel has assessed each trial as it stands alone and has searched for consistency among trials with similar therapy and patient groups.
The panel has also evaluated the evidence from all clinical trials presented at the conference and addressed each question as it relates to specific patient groups at high risk for the development of venous thromboembolic events.
What Is the Level of Risk of Venous Thrombosis and Embolism in Various Patient Groups?
Venous thrombosis and PE constitute major causes of morbidity associated with many common medical conditions and surgical procedures. Reliable natural history data are available from the control arms of well over 100 clinical trials published during the past two decades, generally from patients over the age of 40. European trials document a higher rate of DVT than has been reported in North America, Asia, or Africa, but a significant incidence of these complications has been found in all studies directed at this problem, regardless of the location of the investigation.
The largest pool of data has been obtained in studies of patients over the age of 40 undergoing general surgical procedures, where the average incidence of deep venous thrombosis in control patients is 25 percent by fibrinogen scanning and 19 percent by venography. The pooled data incidence of DVT in Europe is 30 percent, and in North America it is 16 percent. DVT extends proximal to the knee joint in 7 percent, and clinically significant pulmonary embolism occurs in 1.6 percent of the general surgical population. Finally, the likelihood of a major pulmonary embolus leading to death approaches 1 percent. Advancing age and malignancy are associated with even higher rates of both DVT and PE.
All elective orthopedic surgical patients undergoing lower extremity surgery are at risk for deep venous thrombosis. The risk to patients is greatest for hip surgery and knee reconstruction, where DVT rates range from 45 to 70 percent.
Clinically significant PE has been reported to be as high as 20 percent in hip surgery patients, with a 1 to 3 percent incidence of fatal PE. The rates of both clinical PE and fatal PE following knee reconstruction are lower than following hip surgery but remain a problem.
The incidence of DVT in urologic surgery is similar to that in general surgery, that is, about 25 percent, and ranges from 40 percent in transvesical prostatectomy to 10 percent in transurethral surgery. Because increasing age has a high correlation with increased risk of DVT, urologic patients often have a higher risk than other surgical patients.
Gynecology and Obstetrics
The reported overall risk of DVT in gynecologic surgery ranges from 7 to 45 percent. Fatal PE is estimated to occur in nearly 1 percent of these patients. Low-risk patients include those up to 40 years of age undergoing surgical procedures of less than 30 minutes, and in this group, the incidence of DVT is under 3 percent. Moderate-risk patients, 40 to 70 years of age, undergoing minor or major surgery with no other risk factors, have a 10 to 40 percent risk of DVT. High-risk patients, age 40 or over with added risk factors (prior DVT/PE, varicose veins, infection, malignancy, estrogen therapy, obesity, and prolonged surgery), have a 40 to 70 percent risk of DVT and a 1 to 5 percent risk of fatal PE.
The risk of DVT in pregnancy has been reported to be five times higher than in nonpregnant patients in the same age group and may be increased post partum. Antenatal risks are increased in patients with prior DVT or PE, varicose veins, and obesity. It is not known whether these risks are additive. Postpartum risks are increased by Cesarean delivery, which carries risks similar to those of gynecologic surgery.
Neurosurgery and Neurology
The risk of DVT and fatal PE in neurosurgical patients is similar to that of other surgical high-risk groups. The incidence of DVT ranges from 9 to 50 percent. Fatal PE occurs in from 1.5 to 3 percent. In stroke, the risk of DVT in the paralyzed leg is as high as 75 percent, whereas in the nonparalyzed leg it is approximately 7 percent.
The risks of thromboembolic diseases and subsequent PE have not been specifically defined for the general trauma population. This is due in part to the complex nature and wide variety of systems injured. In addition, the most prevalent diagnostic test used for DVT, the 125I-fibrinogen uptake, cannot be used effectively in this population because tissue trauma itself can produce a positive scan. Although data are lacking, it is estimated that the incidence of DVT in the young multisystem trauma patient is about 20 percent. The incidence of fatal PE is not known. Two subgroups of trauma patients have a much higher risk of thrombosis. The elderly patient with a hip fracture has a reported incidence of DVT exceeding 40 percent and an incidence of fatal PE exceeding 4 percent. The patient with an acute head or spinal cord injury has a reported 40 percent incidence of DVT and a greater than 1 percent incidence of fatal PE.
Two groups of medical conditions exist in which the incidence of thromboembolism is greatly increased (Table 1). One group consists of inherited deficiencies of inhibitors and regulators of coagulation or fibrinolysis. These inherited conditions are associated with a positive family history for thromboembolism, onset at an early age, and repeated episodes of thromboembolism, often in the absence of other known predisposing factors. Although the exact cumulative risk of thromboembolism is not known in most of these uncommon genetic disorders, it approaches 80 percent in antithrombin III deficiency.
A much larger group encompasses patients with acquired conditions predisposing to thromboembolism. The risk of thromboembolism in this group of patients ranges up to 80 percent in paroxysmal nocturnal hemoglobinuria, up to 70 percent in congestive heart failure, and up to 40 percent in acute myocardial infarction.
In patients from either category, the risk for thromboembolism is heightened by the presence of additional risk factors--but by an unknown amount.
Table 1. Risk Factors Predisposing to Thromboembolism
Within the broad scope of general surgery, low-dose heparin administered subcutaneously every 8 or every 12 hours beginning 2 hours prior to surgery reduces the rate of DVT by 60 percent, for a net decrease in incidence from 25 percent to 10 percent. In pooled studies, the likelihood of a calf thrombus extending proximally is reduced by approximately one-half, as is the risk of clinically significant PE. Finally, fatal PE decreases from 0.7 to 0.2 percent. Heparin-associated thrombocytopenia has been reported rarely in patients receiving low-dose heparin.
Although fewer data are available, dextran-70 exerts a comparable protective effect in decreasing PE, but a lesser decrease in DVT. Dextran-40 appears to have a similar effect. The use of a combination of dihydroergotamine and heparin, as well as the use of external pneumatic compression, produce comparable benefits with respect to DVT, but fewer patients have been studied with these modalities. The use of graduated compression elastic stockings has also been reported to be of benefit, but even fewer patients have been studied and stockings must be carefully fitted if they are to have prophylactic merit. The likelihood of benefit with any of these methods suggests that the prophylactic treatment of 200 patients will prevent 1 death from PE, 1.2 episodes of clinically significant PE, and 20 episodes of DVT. No benefits were associated with aspirin prophylaxis. Both heparin and dextran increase the risk of bleeding and hematoma formation, but the risk of serious complications or death is minimal. The side effects of external pneumatic compression and elastic stockings are limited to patient discomfort and subsequent failure of compliance.
Despite the effectiveness of low-dose heparin in other situations, it may be less beneficial in orthopedic patients. Dextran and warfarin have been shown to reduce the incidence of DVT by a factor of two in controlled trials in patients undergoing elective hip surgery and knee reconstruction. Rates of clinical PE are also reduced, but the lowered death rate from PE, while suggestive, is not statistically significant.
Elevation of the foot of the bed, gradient elastic stockings, and external pneumatic compression also reduce the incidence of DVT significantly. The use of these mechanical measures is without known complications.
Warfarin and dextran in commonly used doses can cause complications of operative bleeding and wound hematomas. Congestive heart failure, renal failure, and anaphylaxis are uncommon complications of dextran. Fatal hemorrhage has been reported with warfarin. The incidence of these bleeding complications is not well documented in orthopedic surgery. Wound hematomas can be a significant problem in joint replacement patients. Small-scale studies suggest that low-dose warfarin may be safe, but the data are limited.
The efficacy of prophylaxis for DVT in urologic patients has been studied most extensively with low-dose heparin. In several studies, the reduction in incidence following prophylaxis is 75 percent--similar to data from general surgery. Small-scale studies using external pneumatic compression suggest a decrease in DVT similar to that in patients receiving low-dose heparin.
Low-dose heparin appears safe as measured by transfusion requirements and the postoperative decrease in hemoglobin concentration. External pneumatic compression also appears to carry no significant risk.
Gynecology and Obstetrics
The evidence suggests that for low-risk patients with little chance of DVT, early ambulation and graduated compression stockings are sufficient prophylaxis. Patients at moderate to high risk, with benign disease, can be managed effectively with low-dose heparin, dextran, and/or external pneumatic compression with comparable results. Some evidence suggests that low-dose heparin is ineffective for prophylaxis in patients with gynecologic malignancy. In this category, dextran, warfarin, and/or external pneumatic compression can be effective. Although data are lacking, the panel believes that warfarin also may provide effective and safe prophylaxis for patients with benign or malignant disease.
Data from controlled trials are lacking for pregnant and postpartum patients. However, the panel believes that low-dose heparin may be effective and safe for prophylaxis when used antenatally in pregnant patients at risk. There are no data regarding the optimal timing of therapy. Warfarin prophylaxis is contraindicated in pregnancy, and there are no data on the use of dextran in pregnancy. The panel believes that low-dose heparin and/or external pneumatic compression may be effective and safe in prophylaxis in postpartum patients at risk.
Neurosurgery and Neurology
There is a relative paucity of studies on specific therapies for special subgroups of neurosurgical patients as compared with general and orthopedic surgery patients. The efficacy of external calf compression, low-dose heparin (with or without dihydroergotamine), and warfarin has been demonstrated for patients with extracranial problems.
Patients with intracranial lesions and spinal lesions for which even minor bleeding complications could have disastrous effects are generally not considered candidates for prophylaxis with anticoagulants, although limited data support the use of low-dose heparin as safe for selected craniotomy patients. External pneumatic compression is recommended for patients with this group of problems and has been shown to be both efficacious and safe.
The specific risks of bleeding dictate the manner and type of prophylaxis to be used in the trauma patient. The elderly patient with a hip fracture is at high risk for thromboembolic complications and clearly requires some form of prophylaxis for at least 7 days or until ambulatory. One can choose from three effective measures: dextran, external pneumatic compression, or pressure gradient elastic stockings may be useful. The efficacy of low-dose warfarin in hip fracture patients is not known. Aspirin and low-dose heparin are of no benefit.
Head injury and acute spinal cord injury patients also require prophylaxis. To minimize the high risk of bleeding, external pneumatic compression and pressure gradient elastic stockings are the methods of choice.
For severe musculoskeletal trauma, prophylaxis is indicated until the patient is ambulatory. Low-dose heparin or dextran is effective in young patients if initiated early. External pneumatic compression and gradient compression stockings are effective alternatives for decreasing lower leg thrombosis if lower extremity trauma does not preclude their use. In multisystem trauma, anticoagulants should be used with caution until the types of injuries present have been assessed and initial bleeding controlled.
Limited clinical trials support the use of low-dose heparin for patients with heart failure, acute myocardial infarction, or pulmonary infection to prevent DVT. Although studies do not exist to support extension of these observations to other medical patients at bed rest and at risk for thromboembolism, administration of low-dose heparin may be indicated, especially as long as other conditions predisposing to DVT coexist. Where long-term prophylaxis is indicated in chronic high-risk patients, warfarin therapy is appropriate.
Disclaimer: This information is intended as a guide only. This information is offered to you with the understanding that it not be interpreted as medical or professional advice. All medical information needs to be carefully reviewed with your health care provider.